文献速递神经肿瘤

功能性Crooke细胞腺瘤:病例系列与文献综述

Functioning Crooke Cell Adenomas: Case Series and Literature Review.
PubMed 文献 · World Neurosurg · 2021-11-18

该研究回顾性分析了2017年10月至2020年11月间手术的59例连续性功能性促肾上腺皮质激素腺瘤,其中Crooke细胞腺瘤(CCA)占8.5%(5/59)。5例患者术后3个月均获生化缓解,随访3.1-31.0个月无影像学或生化复发;文献综述汇总22例功能性促肾上腺皮质激素腺瘤,部分病例对标准治疗难治。

要点

  • 本机构功能性促肾上腺皮质激素腺瘤中CCA患病率为8.5%(5/59),其他4个手术病例系列为0%-6.8%。
  • 5例CCA患者中3例为大腺瘤,2例有海绵窦侵犯,所有患者术后3个月达生化缓解。
  • 文献综述中22例功能性促肾上腺皮质激素腺瘤的额外治疗包括再手术(50%)、放疗(59%)、双侧肾上腺切除术(23%)和替莫唑胺(36%)。

核心结论

  • 在实施2017年世界卫生组织分类后,本机构功能性促肾上腺皮质激素腺瘤中CCA患病率较高,本系列术后结局优异,而文献中部分病例对标准治疗难治,需更大规模临床与分子研究识别高危患者。

研究设计与样本

  • 回顾性综述2017年10月至2020年11月间手术的59例连续性功能性促肾上腺皮质激素腺瘤,并对1991年以来CCA文献进行综述。

主要发现

  • 本机构CCA在功能性促肾上腺皮质激素腺瘤中患病率为8.5%(5/59),其他4个手术病例系列为0%-6.8%。
  • 5例患者(4女1男,平均年龄46±11岁)中3例表现为皮质醇增多症,1例视力丧失,1例偶然发现。
  • 所有患者促肾上腺皮质激素升高(151±54 pg/mL),尿游离皮质醇升高(830±796.5 μg/天)。
  • 影像学上3例为大腺瘤,2例有海绵窦侵犯;所有患者术后3个月达生化缓解,1例巨大垂体腺瘤因残留肿瘤接受分次放疗。
  • 随访3.1-31.0个月期间无影像学或生化复发证据;文献综述纳入22例功能性促肾上腺皮质激素腺瘤的结局数据。

关键数值与推荐

  • 文献综述中22例功能性促肾上腺皮质激素腺瘤的额外治疗包括再手术(50%)、放疗(59%)、双侧肾上腺切除术(23%)和替莫唑胺(36%)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Crooke cell adenomas (CCAs) are rare, potentially aggressive pituitary adenomas. Data regarding prevalence and clinical course are sparse. METHODS: We performed a retrospective review of 59 consecutive functioning corticotroph adenomas operated on between October 2017 and November 2020 and a literature review of CCA publications since 1991. RESULTS: The prevalence of CCAs among functioning corticotroph adenomas at our institution was 8.5% (5/59). In the 4 other surgical case series, prevalence of CCAs was 0%-6.8%. Our patients (4 women and 1 man, mean age 46 ± 11 years) presented with hypercortisolism (3/5), with vision loss (1/5), and incidentally (1/5). All patients had elevated adrenocorticotropic hormone (151 ± 54 pg/mL) and urinary free cortisol (830 ± 796.5 μg/day). Radiologically, 3 tumors were macroadenomas and 2 had cavernous sinus invasion. All patients achieved biochemical remission at 3 months postoperatively. One patient with a giant pituitary adenoma underwent fractionated radiation for residual tumor. During follow-up (range, 3.1-31.0 months), no patients had evidence of radiological or biochemical recurrence. The literature review identified 22 functioning corticotroph adenomas with outcome data. Additional treatments included reoperation (50%), radiation (59%), bilateral adrenalectomy (23%), and temozolomide (36%). CONCLUSIONS: We found a higher CCA prevalence among functioning adrenocorticotropic hormone adenomas after implementation of the 2017 World Health Organization classification. In our series and the literature, most CCAs were macroadenomas with high adrenocorticotropic hormone levels. Postoperative outcomes were excellent in our series, while some cases from the literature were refractory to standard treatments. Larger clinical and molecular studies are needed to identify patients at risk.

来源:World Neurosurg,查看原文。版权归原作者所有。

引用

  1. Giraldi EA, Neill SG, Mendoza P, et al. Functioning Crooke Cell Adenomas: Case Series and Literature Review. World Neurosurg. 2021. PMID: 34800730. doi:10.1016/j.wneu.2021.11.049

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。